目的 評價癃清片聯(lián)合化學藥治療III型前列腺炎［即慢性前列腺炎/慢性盆腔疼痛綜合征（CP/CPPS）］的療效及安全性。方法 檢索PubMed、Embase、Medline、Web of Science、Cochrane Library、中國學術(shù)期刊全文數(shù)據(jù)庫（CNKI）、萬方數(shù)據(jù)知識服務(wù)平臺（Wanfang Data）、維普中文科技期刊數(shù)據(jù)庫（VIP）、中國生物醫(yī)學文獻服務(wù)系統(tǒng)（SinoMed）等數(shù)據(jù)庫自建庫至2022年1月關(guān)于癃清片治療CP/CPPS的臨床隨機對照試驗（RCT），根據(jù)納排標準篩選文獻，并采用Revman 5.4軟件進行Meta分析。結(jié)果 共納入8項RCTs，共計1 000例患者，其中試驗組503例、對照組497例。Meta分析結(jié)果顯示治療后試驗組美國國立衛(wèi)生院慢性前列腺炎癥狀評分癥狀總分［MD=?2.65，95% CI（?3.28，?2.03），P＜0.000 01］、疼痛癥狀評分［MD=?1.44，95% CI（?1.95，?0.92），P＜0.000 01］、生活質(zhì)量評分［MD=?0.50，95% CI（?0.93，?0.06），P=0.03］均低于對照組；排尿癥狀評分與對照組比較差異不顯著［MD=?0.17，95% CI（?0.85，0.50），P=0.61］，敏感性分析顯示對照組干預(yù)措施僅應(yīng)用1種化學藥，則差異具有統(tǒng)計學意義［MD=?0.75，95% CI（?1.43，?0.07），P=0.03］；前列腺按摩液中白細胞計數(shù)低于對照組［MD=?4.33，95% CI（?6.59，?2.08），P=0.002］；不良反應(yīng)發(fā)生率與對照組比較差異不顯著［RR=1.00，95% CI（0.46，2.19），P=0.99］。結(jié)論 癃清片能顯著改善CP/CPPS患者癥狀，降低前列腺按摩液中白細胞數(shù)量，且不會顯著增加不良反應(yīng)的發(fā)生。

Objective To evaluate the efficacy and safety of Longqing Tablet combined with pharmaceutical chemicals in the treatment of type III prostatitis, which is chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods Data were electronically searched from the PubMed, Embase, Medline, Web of Science, Cochrane Library, CNKI, Wanfang Data, VIP, and SinoMed to collet randomized controlled trails (RCTs) on Longqing Tablet in the treatment of CP/CPPS. The retrieval time was from database establishment to January 2022. The literatures were screening according to inclusion criteria and exclusion criteria. The Meta-analysis was carried out by Revman 5.4 software. Results A total of eight RCTs were selected, including 1 000 cases (503 cases in the experimental group and 497 cases in the control group). Meta-analysis showed that the NIH-CPSI symptom score (total score) is lower than that of the control group [MD = -2.65, 95%CI (-3.28, -2.03), P<0.000 01]. The pain symptom score is lower than that of the control group [MD = -1.44, 95%CI (-1.95, -0.92), P<0.000 01]. The quality of life score is lower than that of the control group [MD = - 0.50, 95%CI (- 0.93, - 0.06), P=0.03]. There are no significant differences in voiding symptom score between control group and control group [MD=-0.17, 95%CI (-0.85, 0.50), P=0.61], but there are significant differences between experimental group and control group when only use one pharmaceutical chemical in the control group [MD=-0.75,95%CI (-1.43, -0.07), P = 0.03]. The EPS leukocyte count is lower than that of the control group [MD=-4.33,95%CI (-6.59, -2.08), P=0.002]. Finally, there is no significant difference in adverse reaction rate compared with the control group [RR = 1.00, 95%CI (0.46, 2.19), P=0.99]. Conclusion Longqing Tablet can improve the symptoms and reduce leukocyte count of EPS in CP/CPPS patients significantly. Moreover, it do not increase the incidence of adverse reactions significantly.

R287.3

中國中醫(yī)科學院科技創(chuàng)新工程項目(CI2021A00905);中國中醫(yī)科學院基本業(yè)務(wù)費自主選題項目(Z0546)